Sign up to receive latest insights & updates in technology, AI & data analytics, data science, & innovations from Polestar Analytics.
| HCP engagement improves when quarterly strategy reaches every rep as named doctors and next best actions, not aggregate dashboards refreshed weekly. |
TL;DR
Only 12% of CEOs told, in PwC's 29th Annual Global CEO Survey in January 2026, that AI has produced both revenue gains and cost savings in the last twelve months. 56% reported neither. Pharma commercial teams sit inside that majority. Not for lack of data or models, the gap is that strategy never reaches the rep in a form the rep can act on, and by the third week of the quarter that shows up as tier-1 doctors quietly slipping down the queue.
The arithmetic is unforgiving: A large pharma commercial organisation typically has tens of thousands of target HCPs and only a few thousand reps to reach them, with each rep working a tiered monthly target list.
Execution drifts within days. A rep waiting on a tier-1 specialist steps into the tier-3 clinic next door because it is closer and friendlier. Good conversation, almost no prescribing consequence.
Nothing in the stack catches this in time. Three structural reasons:
The consequence is that nobody finds out in time. Deloitte's midyear 2026 outlook found only 45% of life sciences executives could point to measurable improvement from their AI investments, and just 13% at scale. A business unit leader who learns at quarter close that coverage was thin cannot tell whether the cause was one rep, one territory, or systemic. That is why a good strategy stops working by week three. Not because anyone rejected it, but because nothing in the stack tells a rep which doctor to see on Tuesday, and nothing tells a manager it went wrong until the quarter is already spent.
Most HCP engagement tools track well enough. The CRM captures every interaction and the dashboards report every KPI. The break is one layer up, where the quarter's priorities sit hard-coded into the reporting logic. Change the strategy and someone has to rebuild the filters and target lists by hand.
HCPPulse inverts that. A Chief Commercial Officer or business unit leader writes a free-text objective for the quarter: protect the existing patient base, or win competitive battles at 50% weighting. That document becomes live context. Every rep's ranked list of doctors is redrawn against the new objective, with names, tiers and reasons attached, and every layer above sees the same re-derivation rolled up: RSD, ESD, BUL, CCO. No dashboard rebuild, no waiting for the monthly refresh.
Static tools need a rebuild when priorities move. An adaptive HCP engagement platform re-prioritises that afternoon.
Two design consequences follow:
Polestar Analytics builds this on the foundation set out in its pharmaceutical analytics practice, where the recurring failure is sequencing: platforms bought before the workflow exists to act on them. The same argument is developed in this analysis of commercial analytics in pharma. Inside HCPPulse, that workflow runs as a five-stage loop:
Each loop closes in days, not quarters. That cadence is the product.
Omnichannel HCP engagement fails at sequencing, not reach. Adding email, remote HCP engagement and digital detailing to an unprioritized call plan multiplies noise.
HCPPulse treats channel as an output of priority, not a parallel programme. Once an HCP is flagged, the recommended action specifies the channel: an in-person call, an email, a webinar invite, a sample drop. Multichannel HCP engagement becomes a scheduling decision inside one queue.
Two capabilities make this defensible at scale:
The traceability point matters more than it reads. McKinsey's State of AI trust research, March 2026, found close to two-thirds of respondents named security and risk concerns the leading barrier to scaling agentic AI, ahead of regulatory uncertainty and technical limits. In a regulated function, traceability is what unlocks adoption, not accuracy alone.
Field force effectiveness is funded as a targeting problem and lost as a translation problem. Segmentation is usually sound. What breaks is the last mile between a quarterly objective and a rep's Tuesday. A platform that reports coverage without naming the missed prescriber has described the symptom and left the diagnosis to the manager. The test in 2026: when strategy changes Monday, does the rep's queue change Tuesday, and can you trace why?
Discover how AI-driven HCP segmentation helps pharma teams identify high-value HCPs, optimise field-force prioritisation, and deliver more relevant next-best actions.
Explore AI-Driven HCP SegmentationThree layers, three jobs. CRM records the interaction. BI reports it in aggregate afterwards. An HCP engagement platform is the prescriptive layer in between: which HCPs matter this quarter, why, and what the rep does next. HCPPulse syncs bidirectionally with Veeva, so the system of record stays unchanged.
Channel breadth without prioritisation increases contact volume, not share. Sequencing is the lever. When priority is derived first, digital HCP engagement and remote HCP engagement become channel choices attached to a specific doctor and reason, which is what makes attribution possible.
Three mechanisms: no recommendation auto-applies without human acceptance, every agent run is traceable to its prompt, tool calls, tokens and output, and responsible-AI adherence is documented with live metrics. Polestar Analytics covers the wider pattern in agentic AI use cases for pharmaceuticals and life sciences.
No, and the boundary is deliberate. Segmentation is an upstream process with its own algorithms. HCPPulse assumes tiering exists and owns the reach-out layer above it. For the segmentation and sizing side of pharma field engagement, this sales force effectiveness eBook is the starting point.
HCPPulse is part of the Polestar Analytics Pulse suite. Pair it with incentives that reward priority-weighted coverage, a theme in reinventing incentive compensation in pharma.